PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21308385-2	2011	Our objective is to look after predictive factors of NAbs development in MS IFN Beta-1b-treated patients.	nabs	53-57	interferon alpha 1	Homo sapiens	76-79	
21308385-6	2011	Sixteen patients had become NAbs positive at some point on IFN therapy (35%).	nabs	28-32	interferon alpha 1	Homo sapiens	59-62	
15549353-1	2004	A proportion of people with multiple sclerosis (MS) treated with interferon (IFN) a develop neutralising anti-IFN beta antibodies (NABs).	nabs	131-135	interferon alpha 1	Homo sapiens	65-75	
15549353-1	2004	A proportion of people with multiple sclerosis (MS) treated with interferon (IFN) a develop neutralising anti-IFN beta antibodies (NABs).	nabs	131-135	interferon alpha 1	Homo sapiens	77-80	
15045868-1	2004	Patients with multiple sclerosis receiving interferon beta (IFN) may develop neutralizing anti-interferon beta antibodies (NABs).	nabs	123-127	interferon alpha 1	Homo sapiens	60-63	
15045868-3	2004	This paper presents the consequences of NABs formation during IFN therapy.	nabs	40-44	interferon alpha 1	Homo sapiens	62-65	
14610106-3	2003	Antibody results need to be represented in a reproducibly quantitative manner to know what proportion of patients treated with an IFN preparation form NAbs and whether the levels of antibody measured are likely to have clinically adverse effects; however, antibody titers have been reported in various ways.	nabs	151-155	interferon alpha 1	Homo sapiens	130-133	
22967100-10	2012	Our analyses revealed that the emergence of anti-IFN-alpha NAbs was a candidate causal factor of PEG-IFN-alpha-treatment failure.	nabs	59-63	interferon alpha 1	Homo sapiens	49-58	
22967100-10	2012	Our analyses revealed that the emergence of anti-IFN-alpha NAbs was a candidate causal factor of PEG-IFN-alpha-treatment failure.	nabs	59-63	interferon alpha 1	Homo sapiens	101-110